Skip to content
CHE

Chemed Corporation

Chemed Corporation Q4 FY2025 earnings call

February 26, 2026 · fiscal period ended 2025-12

EPS · actual vs est

$6.42 / $7.02Miss -8.5%

Revenue · actual vs est

$639.3M / $666.2MMiss -4.0%
Ask about this call

Summary

Generated 2026-02-26

Management highlights

  • VITAS: Transitioned admission pattern to more hospital-directed admissions in Florida combined program, beginning to balance mix. Received CON to operate in Manatee County. Medicare cap billing limitation in Florida is behind us.
  • Rotorooter: Continuing to add commercial business managers, contracted with new SEO provider, working on centralizing water restoration billing and collections to improve results.
View in transcript ↓

Segment performance

VITAS: Fourth quarter 2025 net revenue was $418.8 million, up 1.9% y-o-y. Average daily census was 22,462, up 1.3%. Hospital-directed admissions increased 9.9%. Medicare cap billing limitation in fourth quarter was less than $2 million. Rotorooter: Fourth quarter revenue declined 3.7% y-o-y. Branch commercial revenue increased 1.6%, branch residential revenue declined 3.1%. Water restoration write-offs increased. Total leads were flat, with paid leads up 9.4% but natural leads down. Roto-Rooter Management contracted with new SEO provider.

View in transcript ↓

Guidance

VITAS: Revenue prior to Medicare cap estimated to increase 5.5%-6.5% y-o-y in 2026. Average daily census estimated to increase 3.5%-4%. Full-year EBITDA margin prior to Medicare cap 17.5%-18%. Medicare cap billing limitations estimated at $9.5 million in 2026. Rotorooter: Forecasted full-year 2026 revenue growth 3%-3.5%. Adjusted EBITDA margin 22.5%-23%. Full-year 2026 earnings per diluted share estimated $23.25-$24.25.

View in transcript ↓

Risks

Private equity disruption in plumbing industry affecting paid search model. Google algorithm changes impacting natural search leads. Increased water restoration write-offs due to insurance scrutiny and inconsistent billing practices.

View in transcript ↓

Q&A highlights

Q: What gives confidence in Roto-Rooter revenue growth in 2026?

A: Paid leads increasing, improved visibility through SEO, potential acquisition of other franchises.

Q: How to think about VITAS revenue progression?

A: Patient mix with short-stay patients building over year, refocusing admission pattern to normalize growth.

Q: Structural change in Roto-Rooter?

A: Going through transition with paid leads instead of free, but no long-term impairment, focusing on leads and ancillary services.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$6.42$7.02-8.5%
Revenue$639.3M$666.2M-4.0%

Transcript

February 26, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.